FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	l.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Malik Fady Ibraham					2. Issuer Name and Ticker or Trading Symbol <u>CYTOKINETICS INC</u> [CYTK]								5. Relationship of Report (Check all applicable) Director			ng Person(s) to Issuer 10% Owner			
(Last)	(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 02/06/2024									A below)	fficer (give title elow) VP Research & Development			, ,	
					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X Form filed by One Reporting Person					
SOUTH SAN FRANCISCO CA 94080															Form filed by More than One Reporting Person				
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication													
					X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - No	n-Deriv	vativ	e Se	curit	ies Ac	quire	d, Di	sposed c	of, or Be	neficia	ly Owned	l				
(2. Transaction Date (Month/Day/Year)		ear) i	2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.					Benefici Owned I	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Cod	, v	Amount	(A) o	r Price	Reporte Transac (Instr. 3	tion(s)	(s) (4)		(Instr. 4)	
Common Stock 02/0					6/202	/2024			M ⁽¹	M ⁽¹⁾ 2		28,605 A		7 175	175,578		D		
Common Stock 02/06				5/2024				S ⁽¹⁾		28,60	5 D	\$79.	3 146	146,973		D			
Common Stock 02/0				02/06	6/2024				S ⁽¹⁾		4,000) D	\$79.2	28 142,973			D		
		-									oosed of, converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d Date,	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisa Expiration Date (Month/Day/Yea		isable and te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owner Form Direct or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (Right to	\$6.67	02/06/2024			M ⁽¹⁾			28,605	03/23/2	016	02/23/2026	Common Stock	28,605	\$0	57,20	9	D		

Explanation of Responses:

1. Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023.

/s/ John Faurescu, attorney-in-02/06/2024 fact for Dr. Malik

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.